Multiplexed Immunofluorescence for Colorectal Cancer Progression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current digital pathology systems lack the molecular precision and depth of quantitative analysis needed to optimally predict outcomes, guide targeted therapies, and research molecular mechanisms in colorectal cancer.

Innovation Solution

The method involves analyzing colorectal cancer tissue samples using immunofluorescence assays to quantify markers like pan-cytokeratin and E-cadherin in tumor and nontumor cells, and comparing these ratios to distinguish between progressive and nonprogressive colorectal cancer.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional H&E-based histopathology and basic IHC are used, then the diagnostic process remains simple and accessible, but the molecular precision and depth of quantitative analysis are insufficient to optimally predict outcomes and guide targeted therapies

Engineering Contradiction:

Improvemolecular precision and depth of quantitative analysisVSAvoidcomplexity of imaging and analysis system

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent segments the tissue analysis into multiple independent marker channels (e.g., p53, Ki-67, E-cadherin, β-catenin) that can be individually quantified and analyzed. This allows complex molecular data to be broken down into discrete, measurable components that can be processed systematically to predict cancer progression and guide therapy selection.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent transitions from two-dimensional H&E staining to multiplexed immunofluorescence imaging that provides three-dimensional molecular data by detecting multiple protein markers simultaneously at the single-cell level. This dimensional expansion enables quantitative analysis of marker expression patterns, cellular localization, and spatial relationships that were inaccessible to conventional methods.

Inventive Principle:

Principle #17Another dimension (Dimensionality change)

2Reliability

If multiplexed immunofluorescence imaging is used to achieve deep molecular analysis, then outcome prediction and therapy guidance improve, but the complexity of data acquisition and analysis increases

Engineering Contradiction:

Improveaccuracy of outcome prediction and therapy guidanceVSAvoidcomplexity of multiplexed imaging system and data analysis

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs a universal multiplexed immunofluorescence platform that can simultaneously detect multiple cancer-related markers (p53, Ki-67, E-cadherin, β-catenin) in a single tissue section. This multi-functional system enables comprehensive molecular profiling that predicts both tumor progression and response to targeted therapies, eliminating the need for separate staining procedures.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent introduces computational algorithms and image analysis software as intermediaries to bridge the gap between complex multiplexed imaging data and clinical decision-making. These intermediaries automatically quantify marker expression, identify cellular phenotypes, and generate predictive models that translate complex molecular data into actionable clinical insights.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Loss of information

If single-cell level analysis is performed to understand molecular mechanisms, then research into disease mechanisms improves, but the time and resources required for analysis increase

Engineering Contradiction:

Improvedepth of molecular mechanism insightVSAvoidtime required for comprehensive analysis

Core Design Contradiction:

Loss of informationVSLoss of time

Solution Approach 1:

The patent performs preliminary tissue preparation and staining in a standardized protocol that enables subsequent high-throughput imaging and analysis. By preparing tissue sections and applying multiple fluorophore-conjugated antibodies in a predetermined sequence, the system optimizes signal quality and reduces analysis time while maintaining single-cell resolution for deep molecular mechanism investigation.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for accurate differentiation between progressive and nonprogressive colorectal cancer, enabling more effective treatment strategies and improved patient outcomes.

Implementation Method 1

analyzing colorectal cancer tissue samples using immunofluorescence assays to quantify markers like pan-cytokeratin and E-cadherin

Methodology Applied

Scientific EffectImmunofluorescence: Fluorescence

Data Source

PatentUS20250164491A1Methods of Identifying and Treating Progressive Colorectal Cancer

Publication Date: 2025.05.22 THE BRIGHAM & WOMEN S HOSPITAL INC

AI summary

Methods are provided for identifying progressive colorectal cancer within an individual, and to methods of treating progressive colorectal cancer.